Biotech Values

[DewDiligence]

SYT +3% on 4Q14 results/2015 outlook…

SYT forecasts flat 2015 sales and EBITDA in constant currencies, but a $150M benefit from lower oil prices in 2016 due to the time lag for SYT’s oil-based input costs to fall.

SYT pulled its prior guidance for 2020, acknowledging that the targets can't be achieved given the strength of the Swiss Franc and lower than expected crop prices.

SYT derived 53% of 2014 sales from emerging markets.

4Q14 PR:
http://www.syngenta.com/global/corporate/SiteCollectionDocuments/pdf/media-releases/en/20150204-en-full-year-results-2014.pdf

CC slides:
http://www.syngenta.com/global/corporate/SiteCollectionDocuments/pdf/presentations/investor/20150204-analyst-presentation-fyr2014.pdf

10-minute interview with CEO: